Brought to you by 
VaxInnate's $30mm Series D supports swine flu vaccine candidate
13 May 2009
Executive Summary
Vaccines developer VaxInnate completed a $30mm Series D financing to lead and first-time backer Wellcome Trust, which adds a board member. Returning shareholders CHL Medical Partners, Canaan Partners, HealthCare Ventures, MedImmune Ventures, New Leaf Venture Partners, and Oxford Bioscience Partners also participated. The money will support clinical trials of various infectious disease vaccines, as well as the continued development of a prototype swine flu vaccine, which should enter preclinical studies in about a month. It is possible that at the government's request, VaxInnate could begin manufacturing a swine flu vaccine within weeks of the product's approval to meet the needs of the current global crisis. To date the company has raised about $95mm in venture funding.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
VaxInnate's $30mm Series D supports swine flu vaccine candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice